Last reviewed · How we verify
Eye Associates of Central Texas — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Fluoromethalone .01% | Fluoromethalone .01% | marketed | Topical corticosteroid | Glucocorticoid receptor | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Al-Azhar University · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- Apotex Inc. · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Astion Pharma A/S · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Eye Associates of Central Texas:
- Eye Associates of Central Texas pipeline updates — RSS
- Eye Associates of Central Texas pipeline updates — Atom
- Eye Associates of Central Texas pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Eye Associates of Central Texas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eye-associates-of-central-texas. Accessed 2026-05-18.